- the lack of new funds available for investment, and
- the need to deliver a rapid return on investment capital.
- potential collaborators submit compound structures to a confidential on-line evaluation tool
- following evaluation of submitted structures, those deemed interesting to Lilly's programs are selected for screening
- following screening of interesting structures, those with promising activity profiles become subjects for collaborative development activities
The above argument, while presenting a black-and-white picture, does illustrate a trend towards new paradigms in the pharmaceutical industry. Such paradigms clearly depend upon research activities. However, such research activities are executed through peripheral organizations and not within the infrastructure of parent companies. Nobody disputes the fact that without research, there can be no development pipelines. The only real questions are:
- Who does the research?
- Where will research activities be located?